Seongyi Bio

Seongyi Bio is a South Korean biotechnology company focused on developing oral small molecule therapies for metabolic and fibrotic diseases. The company's lead candidate, SYB-01, is an orally available GLP-1 receptor agonist designed to treat obesity and non-alcoholic steatohepatitis (NASH) with improved patient convenience. By targeting the multi-billion dollar metabolic market with a small molecule approach, Seongyi Bio aims to overcome the limitations of current injectable peptide treatments. The company is also advancing SYB-02, a pre-clinical program for idiopathic pulmonary fibrosis, as part of its broader mission to address chronic inflammatory and fibrotic conditions.